Welcome to our dedicated page for Vaxcyte news (Ticker: $PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vaxcyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vaxcyte's position in the market.
Rhea-AI Summary
Vaxcyte, Inc. (Nasdaq: PCVX) appoints Whitney Jones as Chief People Officer to lead human resources strategy and operations, emphasizing a people-first approach to support organizational growth strategies and advance vaccine candidates, including lead pneumococcal conjugate vaccine franchise programs, VAX-24 and VAX-31.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Study, Plans for Phase 3 Pivotal Study and Receives Encouraging Input on CMC Licensure Requirements; Enrollment in VAX-24 Infant Phase 2 Study Progressing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.07%
Tags
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) published results from the VAX-24 Phase 1/2 clinical proof-of-concept study in The Lancet Infectious Diseases. The study demonstrated that VAX-24 had a safety and tolerability profile similar to Prevnar 20® (PCV20) at all doses studied and met or exceeded regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2 mcg dose. The company plans to advance the VAX-24 2.2 mcg dose into a Phase 3 program, with topline data expected in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
Rhea-AI Summary
Vaxcyte, a vaccine innovation company (Nasdaq: PCVX), appointed Jacks Lee to its Board of Directors. The company aims to develop high-fidelity vaccines for bacterial diseases. The appointment aims to leverage Jacks Lee's expertise in biopharmaceutical and vaccine manufacturing, supply, and operations to advance the development and potential global commercialization of Vaxcyte's pneumococcal conjugate vaccine (PCV) candidates, VAX-24 and VAX-31.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) obtains exclusive rights to develop and manufacture cell-free extract, a key component of the company’s pneumococcal conjugate vaccine (PCV) franchise. This strengthens Vaxcyte’s global commercial manufacturing strategy as lead PCV candidate, VAX-24, advances into Phase 3. Vaxcyte exercised its option and entered into a manufacturing rights agreement with Sutro Biopharma, Inc. (STRO) to obtain control over the development and manufacture of cell-free extract for its vaccine candidates. The agreement involves a $50 million cash payment to Sutro, with an additional $25 million to be paid within six months, and potential milestone payments totaling up to $60 million in cash upon the occurrence of certain regulatory milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
-
Rhea-AI Summary
PCVX - Vaxcyte, Inc. Announces Initiation of Phase 1/2 Clinical Study for VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine Candidate, with Broadest-Spectrum Coverage and Topline Safety Data Expected in Second Half of 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
Rhea-AI Summary
Vaxcyte, Inc. has announced financial results for Q3 2023 and provided a business update. The company completed a successful End-of-Phase 2 meeting with the FDA for VAX-24, with topline Phase 3 data expected in 2025. They also received FDA clearance for VAX-31 Adult IND Application, with Phase 1/2 study initiation expected this quarter and topline data in the second half of 2024. Vaxcyte has advanced the ongoing VAX-24 Infant Phase 2 study, with topline data expected by 2025. They have also expanded their collaboration with Lonza for global commercial manufacturing of VAX-24 and VAX-31. As of September 30, 2023, the company has $1.4 billion in cash, cash equivalents, and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
-
Rhea-AI Summary
Vaxcyte, Inc. will participate in investor conferences including Guggenheim 5th Annual Inflammation & Immunology Conference, Jefferies London Healthcare Conference, and Evercore ISI 6th Annual HealthCONx Conference. The fireside chats will be live-streamed on the company's website and replays will be available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
-
Rhea-AI Summary
Vaxcyte receives FDA clearance for adult IND application of VAX-31 pneumococcal conjugate vaccine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
Rhea-AI Summary
Vaxcyte to participate in fireside chat at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
Vaxcyte, Inc.
Nasdaq:PCVX
PCVX Rankings
PCVX Stock Data
7.79B
99.20M
0.91%
96.76%
7.62%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
SAN CARLOS
About PCVX
sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax’s lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax’s broad-spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe